For instance, the concentration of programmed death-ligand (PD-L1)-positive and PD-L2-positive dendritic cells in circulation may play a role in the selection of BC patients who are resistant to enzalutamide, as has already been shown for PC patients [45]. The gene discussed is CD274; the disease is pachyonychia congenita.